Opinion

Video

Clinical Insights on Belzutifan in Advanced RCC

Author(s):

Benjamin Garmezy, MD,Martin H. Voss, MD

Following a review of research on belzutifan in the advanced RCC space, the expert panel has a comprehensive discussion on treatment approaches and toxicity management.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Minoo Battiwalla, MD, MS
David Rimm, MD, PhD
Related Content
Anita Scheuber, MD, PhD
October 29th 2024

Novel HPK1 Inhibitor NDI-101150 Shows Early Activity in RCC

Francine Foss, MD, professor, medicine (hematology) and dermatology, director, Multidisciplinary T Cell Lymphoma Program, Yale School of Medicine; scientific leader, Lymphoma CRT, Yale Cancer Center
October 17th 2024

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

Alan Tan, MD
October 18th 2024

Long-Term IO-IO Data Contest the Role of Frontline TKIs in Advanced RCC

Rory Shallis, MD, assistant professor, medicine and hematology, Yale School of Medicine, Yale New Haven Health
September 26th 2024

How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

Chad Tang, MD
October 15th 2024

Prospective Trials Could Refine Potential Roles for Radiation in Advanced RCC

Eric Jonasch, MD, physician, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
October 14th 2024

NKT2152 Generates Responses in Heavily Pretreated Advanced ccRCC